Chapter 7 References -...

Chapter 7 References

Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 183

Abdelwahed W, Degobert G, Stainmesse S, Fessi H (2006). Freeze drying of

nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev.

58: 1688–713.

AHFS Drug Information (2002). American Society of Health-System Pharmacists,

edited by G.K. McEvoy, pp. 1313-1317.

Ahlin P, Kristl J, Kristl A, Vrecer F (2002). Investigation of polymeric nanoparticles

as carriers of enalaprilat for oral administration. Int J Pharm. 239: 113-20.

Ahmad S, Jain GK, Faiyazuddin M, Iqbal Z, Talegaonkar S, Sultana Y, Ahmad FJ

(2009). Stability-indicating high-performance thin-layer chromatographic method for

analysis of terbinafine in pharmaceutical formulations. Acta Chromatogr. 4: 631–

639.

Ahuja S, Ashman J (1990). Terbutaline sulfate. In Analytical Profiles of Drug

Substances edited by K. Florey, Academic Press, New York, pp. 601-625, 1990.

Ali HSM, York P, Blagden N (2009). Preparation of hydrocortisone nanosuspension

through a bottom-up nanoprecipitation technique using microfluidic reactors. Int. J.

Pharm. 375: 107–113.

Ali R, Jain GK, Iqbal Z, Talegaonkar S, Pandit P, Sule S, Malhotra G, Khar RK,

Bhatnagar A, Ahmad F.J (2009a). Development and clinical trial of nano-atropine

sulfate dry powder inhaler as a novel organophosphorous poisoning antidote

Nanomedicine: Nanotechnology, Biology and Med. 5 (1): 55-63.

Altiere RJ, Thompson DC (1996). Pulmonary physiology and pharmacology of the

airways. In Inhalation Aerosols: Physical and Biological Basis for Therapy, pp.

96–9.

Anderson JM, Shive MS (1997). Biodegradation and biocompatibility of PLA and

PLGA microspheres. Adv Drug Del Rev. 28: 5-24.

Andersson KE, Nyberg L (1984). Pharmacokinetics of terbutaline therapy. Eur J

Respir Dis. 65 (134): 165- 170.



Arnold K, Grass P, Knecht A, Roos R, Sluke G, Thieme H, Wenzel J (1995).

Inhalation powders and method of manufacturing them. Eur Patent 0663815.

Asthma and Allergies" (2008). National Institute for Occupational Safety and Health.

http://www.cdc.gov/niosh/topics/asthma/. Retrieved March 23, 2009.

Bailey MM, Berkland CJ (2009). Nanoparticle formulations in pulmonary drug

delivery. Med Res Rev. 29 196–212.

Bansil R, Turner BS (2006). Mucin structure, aggregation, physiological functions

and biomedical applications. Curr Opin Colloid Interface Sci. 11: 164–70.

Barron MK, Young TJ, Johnston KP, Williams III RO (2003). Investigation of

processing parameters of spray freezing into liquid to prepare polyethylene glycol

polymeric particles for drug delivery. AAPS PharmSciTech. 4: E12.

Bates DV, Fish BR, Hatch TF, Mercer TT, Morrow PE (1966). Deposition and

retention models for internal dosimetry of the human respiratory tract. Task group on

lung dynamics. Health Phys.12 (2): 173–207.

Bernard VE, Sofie V, Johan AM, Jan V, Ludo F, Jan VH, Guy VM, Patrick A (2008).

Microcrystalline cellulose, a useful alternative for sucrose as a matrix former during

freeze-drying of drug nanosuspensions–A case study with itraconazole. Eur J Pharm

Biopharm. 70(2): 590-596.

Bernhard W, Haslam PL, Floros J (2004). From birds to humans: new concepts on

airways relative to alveolar surfactant. Am J Respir Cell Mol Biol. 30: 6–11.

Bhavna, Ahmad F, Khar R, Sultana S, Bhatnagar A (2009). Techniques to develop

and characterize nanosized formulation for salbutamol sulfate. J Mater Sci Mater

Med. 20: 71–76.

Bilati U, All´emann E, Doelker E (2005). Development of a nanoprecipitation method

intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm

Sci. 24: 67–75.



Biradar SV, Patil AR, Sudarsan GV, Pokharkar VB (2006). A comparative study of

approaches used to improve solubility of roxithromycin. Powder Technol. 169 (1),

24: 22-32.

Bisgaard H (1996). Drug delivery frominhaler devices. Lung deposition, clinical

effect and cost effectiveness vary. Br Med J. 313: 895–896.

Blondino LFE, Hindle M, Soine WH, Byron PR (2005). Stability and characterization

of perphenazine aerosols generated using the capillary aerosol generator. Int J

Pharm. 303: 113–124.

Borgstrom L, Newman S, Wheisz A, MorCn F (1992). Pulmonary distribution of

inhaled terbutaline: comparison of scanning gamma camera and urinary excretion

methods. J Pharm Sci. 81: 753-755.

Borgstrom L, Nilsson M (1990). A method for determination of the absolute

pulmonary bioavailability of inhaled drugs: terbutaline. Pharm Res. 7: 1069-1070.

Borm P, Klaessig FC, Landry TD, Moudgil B, Pauluhn J, Thomas K, Trottier R,

Wood S (2006). Research strategies for safety evaluation of nanomaterials, Part V:

Role of dissolution in biological fate and effects of nanoscale particles. Toxicol Sci.

90: 23–32.

Bosch HW, Ostrander KD, Cooper ER (2002). Dry powder aerosols of

nanoparticulate drugs. US20020102294.

Bouzigon E, Corda E, Aschard H. (2008). Effect of 17q21 Variants and Smoking

Exposure in Early-Onset Asthma. New Eng Jour Med. 359 (19): 1985–89.

Braun MA, Oschmann R, Schmidt PC (1996). Influence of excipients and storage

humidity on the deposition of disodium cromoglycate (DSCG) in the Twin Impinger.

Int J Pharm. 135: 53–62.

Brittain HG, Fiese EF (1999). Effects of pharmaceutical processing on drug

polymorphs and solvates, In Polymorphism in Pharmaceutical Solids edited by

H.G. Brittain, Marcel Dekker Inc, New York, USA.



Buhling F, Waldburg N, Reisenauer A, Heimburg A, Golpon H, Welte T (2004).

Lysosomal cysteine proteases in the lung: role in protein processing and

immunoregulation. Eur Respir J. 23: 620–28.

Bulsara PA, Roche TC (2005). Dry Powder Composition. US20050244340.

Burgess DJ (2005). Injectable dispersed systems — formulation, processing, and

performance, Taylor & Francis Group, USA.

Byron PR (2004). Drug delivery devices: issues in drug development. Proc Am

Thoracic Soc. 1: 321–328.

Calleja I, Blanco-Prˇııeto MJ, Ruz N, Renedo MJ, Dios-Vi ´ eitez MC (2004). High-

performance liquid-chromatographic determination of rifampicin in plasma and

tissues. J Chromatogr A. 1031: 289–294.

Chan HK (2006). Dry powder aerosol delivery systems: current and future research

directions. J Aerosol Med. 19: 21–35.

Chan HK (2006a). Dry powder aerosol delivery systems: current and future research

directions. J Aerosol Med. 19 (1): 21-27.

Chan HK, Chew NYK (2003). Novel alternative methods for the delivery of drugs for

the treatment of asthma. Adv Drug Deliv Rev. 55: 793–805.

Chan HK, Eberl S, Glover W (2006). Radiolabelling of pharmaceutical aerosols and

gamma scintigraphic imaging for lung deposition. In Encyclopaedia of

Pharmaceutical Technology edited by J. Swarbrick, Informa Healthcare, New York,

pp. 3094–3107.

Chawla A, Taylor KMG, Newton JM, Johnson MCR (1994). Production of spray-

dried salbutamol sulphate for use in dry powder aerosol formulation. Int J Pharm.

108: 233-240.

Chen JF, Zhou MY, Shao L, Wang YY, Yun J, Chew NY, Chan HK (2004).

Feasibility of preparing nanodrugs by high-gravity reactive precipitation, Int. J.

Pharm. 269: 267–274.



Chen X, Young TJ, Sarkari M, Williams III RO, Johnston KP (2002). Preparation of

cyclosporine a nanoparticles by evaporative precipitation into aqueous solution. Int J

Pharm. 242: 3–14.

Chiang PC, Alsup J, Lai Y, Hu Y, Heyde B, Tung D (2009). Evaluation of aerosol

delivery of nanosuspension for pre-clinical pulmonary drug delivery. Nanoscale Res

Lett. 4: 254–261.

Choi HS, Ashitate Y, Lee JH, Kim SH, Matsui A, Insin N (2010). Rapid translocation

of nanoparticles from the lung airspaces to the body. Nat Biotechnol. 28: 1300–3.

Chougule MB, Padhi BK, Jinturkar KA, Misra A (2007). Development of Dry

Powder Inhalers. Recent Patents Drug Del Formulation. 1: 11-21.

Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY (2007). Particle

engineering for pulmonary drug delivery. Pharm Res. 24: 411–437.

Christopher D, Curry P, Doub B, Furnkranz K, Lavery M, Lin K, Lyapustina S,

Mitchell J, Rogers B, Strickland H, Tougas T, Tsong Y, Wyka B

(2003). Considerations for the development and practice of cascade impaction testing

including a mass balance failure investigation tree. J Aerosol Med. 16: 235-247.

Chrystyn H (2006). Closer to an ‘Ideal Inhaler’ with the Easyhaler: an innovative dry

powder inhaler. Clin Drug Invest. 26: 175–183.

Cipolla D, Johansson, E. (2008). AERx pulmonary drug delivery systems. In

Modified Release Drug Delivery Technology (2nd Edn) edited by M.J. Rathbone, J.

Hadgraft, M.S. Roberts, M.E. Lane, pp. 563–571.

Clark AR (1995). Medical aerosol inhalers: past, present and future. Aerosol Sci

Technol. 22: 374–391.

Clunes MT, Boucher RC (2007). Cystic fibrosis: the mechanisms of pathogenesis of

an inherited lung disorder. Drug Discov Today Dis Mech. 4: 63–72.

Crapo JD, Barry BE, Gehr P, Bachofen M, Weibel ER (1982). Cell number and cell

characteristics of the normal human lung. Am Rev Respir Dis. 126: 332–7.



Crowder TM (2003). A guide to pharmaceutical particulate science. Boca Raton,

Florida: Interpharm Press/CRC.

Crowder TM, Rosati JA, Schroeter JD, Hickey AJ, Martonen TB (2002).

Fundamental effects of particle morphology on lung delivery: predictions of Stokes’

law and the particular relevance to dry powder inhaler formulation and development.

Pharm Res. 19: 239–245.

Cryan SA, Sivadas N, Garcia-Contreras L (2007). In vivo animal models for drug

delivery across the lung mucosal barrier. Adv Drug Deliv Rev. 59: 1133– 151.

D. Heng, D.J. Cutler, H.K. Chan, J. Yun, J.A. Raper (2008). What is a suitable

dissolution method for drug nanoparticles? Pharm Res. 25: 1696–1701.

Dai WG, Dong LC, Song WQ (2007). Nanosizing of a drug/carrageenan complex to

increase solubility and dissolution rate. Int J Pharm. 342 (1-2): 201-207.

Dailey la, Schmehl T, Gessler T, Wittmar M, Grimminger F, Seeger W, Kissel T

(2003). Nebulization of biodegradable nanoparticles, impact of nebulizer technology

and nanoparticles characteristics on aerosol features. J Control Rel. 86: 131-44.

Dalvi SV, Dave RN (2009). Controlling particle size of a poorly water-soluble drug

using ultrasound and stabilizers in antisolvent precipitation. Ind Eng Chem Res. 48:

7581–7593.

Dalvi SV, Khopadhyay M (2009). A novel process for precipitation of ultra-fine

particles using sub-critical CO2. Powder Tech. 195(3): 190-195.

Daraghmeh N, Al-Omari MM, Sara Z, Badwan AA, Jaber AMY (2002).

Determination of terbutaline sulfate and its degradation products in pharmaceutical

formulations using LC. J Pharm Biomed Anal. 29: 927–937.

Darquenne C, Prisk G.K (2008). Deposition of inhaled particles in the human lung is

more peripheral in lunar than in normal gravity. Eur J Appl Physiol. 103: 687–695.

Davies NM, Feddah MR (2003). A novel method for assessing dissolution of aerosol

inhaler products. Int J Pharm. 255: 175–187.



Dellamary LA, Tarara TE, Smith DJ, Woelk CH, Adractas A, Costello ML, Gill H,

Weers JG (2000). Hollow porous particles in metered dose inhalers. Pharm Res. 17:

168-174.

Deng Z, Xu S, Li S (2008). Understanding a relaxation behavior in a nanoparticle

suspension for drug delivery applications. Int J Pharm. 351: 236–243.

Dhumal RS, Biradar SV, Paradkar AR, York P (2009). Particle engineering using

sonocrystallization: salbutamol sulphate for pulmonary delivery. Int J Pharm. 368

129–137.

Dickinson PA, Howells SW, Kellaway IW (2001). Novel nanoparticles for pulmonary

drug administration. J Drug Target. 9: 295–302.

Dickson LC, Mac Neil JD, Lee S, Fesser AC (2005). Determination of beta-Agonist

Residues in Bovine Urine Using Liquid Chromatography-Tandem Mass

Spectrometry. JAOAC Int. 88: 46–56.

Dixon DJ, Johnston KP, Bodmeier RA (1993). Polymeric material formed by

precipitation with a compressed fluid antisolvent. AIChE J. 39: 127-139.

Dolenc A, Kristl J, Baumgartner S, Planinšek O (2009). Advantages of celecoxib

nanosuspension formulation and transformation into tablets. Int J Pharm. 376(1-2):

204-212.

Dolovich MB (2009). 18F-fluorodeoxyglucose positron emission tomographic

imaging of pulmonary functions, pathology, and drug delivery. Proc Am Thorac

Soc. 6: 477–485.

Dong Y, Ng WK, Shen S, Kim S, Tan Reginald BH (2009). Preparation and

characterization of spironolactone nanoparticles by antisolvent precipitation. Int J

Pharm. 375 (1-2): 84-88.

Dong Y, Wai Kiong Ng, Jun Hu, Shoucang S, Reginald BH Tan (2010). A continuous

and highly effective static mixing process for antisolvent precipitation of

nanoparticles of poorly water-soluble drugs. Int J Pharm. 386 (1-2): 256-261.



Duddu SP, Sisk SA, Walter YH, Tarara TE, Trimble KR, Clark AR, Eldon MA, Elton

RC, Pickford M, Hirst PH, Newman SP, Weers JG (2002). Improved lung delivery

from a passive dry powder inhaler using an engineered Pulmosphere®powder. Pharm

Res. 19: 689-695.

Dunbar C (2002). Dry powder formulations for inhalation. Drug Deliv Syst Sci. 2:

78–80.

Eberl S, Chan HK, Daviskas E (2006). Spect imaging for radioaerosol deposition and

clearance studies. J Aerosol Med. 19: 8–20.

Edwards D, Batvcky R, Johnston L (2004). Highly efficient delivery of a large

therapeutic mass aerosol. US20040076589.

Edwards D, Caponetti G, Hrkach JS, Lotan N, Hanes J, Langer RS, Ben-jebria AA

(2001). Porous Particles for deep lung delivery. US 20010033830.

Edwards DA, Caponetti GH, Jeffrey S, Lotan N, Justin Ben-Jebria AA, Langer RS

(2005). Development of dry powder inhaler. US20050244341.

Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML (1997).

Large porous particles for pulmonary drug delivery. Science. 276 (5320): 1868–1871.

Edwards DA, Sung J, Pulliam B, Wehrenberg-Klee E, Schwartz E, Dreyfuss P,

Kulkarni S, Lieberman E (2005a). Pulmonary delivery of malarial vaccine in the form

of particulates. WO2005110379.

Eerdenbrugh BV, den Mooter GV, Augustijns P (2008). Top-down production of drug

nanocrystals: nanosuspension stabilization, miniaturization and transformation into

solid products. Int J Pharm. 364 64–75.

El-Chemaly S, Pacheco-Rodriguez G, Ikeda Y, Malide D, Moss J (2009). Lymphatics

in idiopathic pulmonary fibrosis: new insights into an old disease. Lymphat Res Biol.

7: 197–203.

Embleton JK (2000). Inhalation Powders. WO0033789.



Engstrom J, Lai E, Ludher B, Chen B, Milner T, Williams R, Kitto G, Johnston K

(2008). Formation of stable submicron protein particles by thin film freezing. Pharm.

Res. 25: 1334–1346.

Engstrom J, Tam J, Miller M, Williams III RO, Johnston K (2009). Templated open

flocs of nanorods for enhanced pulmonary delivery with pressurized metered dose

inhalers. Pharm Res. 26: 101–117.

Fagerstrom PO (1984). Pharmacokinetics of terbutaline after parenteral

administration. Eur J Respir Dis Suppl. 134: 101-110.

Fanta CH (2009). Asthma. N Engl J Med. 360 (10): 1002–14.

Fesser AC, Dickson LC, MacNeil JD, Patterson JR, Lee S, Gedir R (2005).

Determination of beta-agonists in liver and retina by liquid chromatography-tandem

mass spectrometry. J AOAC Int. 88 (1): 61-69.

Flament MP, Leterme P, Gayot A (2004). The influence of carrier roughness on

adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from

dry powder inhalers. Int J Pharm. 275 (1-2): 201-209.

Foster TP, Leatherman MW (1995). Powder characteristics of proteins spray-dried

from different spray-dryers. Drug Dev Ind Pharm. 21: 1705–1723.

Furuyama A, Kanno S, Kobayashi T, Hirano S (2009). Extrapulmonary translocation

of intratracheally instilled fine and ultrafine particles via direct and alveolar

macrophage-associated routes. Arch Toxicol. 83: 429–37.

Galindo-Rodriguez S, All´emann SE, Fessi H, Doelker E (2004). Physicochemical

parameters associated with nanoparticle formation in the saltingout, emulsification–

diffusion, and nanoprecipitation methods. Pharm Res. 21: 1428–1439.

Gallagher PM, Cof fey MP, Krukonis VJ, Klasutis N (1989). Gas antisolvent

recrystllization: New process to recrystallize compounds insoluble in supercritical

fluids. In Supercritical Fluid Science and Technology edited by K.P. Johnston and



Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L, Zhao W (2008). Studies on

pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm.

355 (1-2): 321-327.

Garekani HA, Sadeghi F, Badiee A, Mostafa SA, Rajabi-Siahboomi AR (2001).

Crystal habit modifications of ibuprofen and their physicomechanical characteristics.

Drug Dev Ind Pharm. 27 (8): 803–809.

Gazic I, Bosak A, Sinko G, Vinkovic V, Kovarik Z. Preparative HPLC separation of

bambuterol enantiomers and stereoselective inhibition of human cholinesterases

(2006). Anal Bioanal Chem. 385: 1513–1519.

Geiser M (2010). Update on macrophage clearance of inhaled micro- and

nanoparticles. J Aerosol Med Pulm Drug Deliv. 23: 207–17.

Gonda I (2004). Targeting by deposition. In Pharmaceutical Inhalation Aerosol

Technology edited by A.J. Hickey, Marcel Dekker, Inc., New York, USA, pp. 65–88.

Gupta R, Hindle M, Byron PR, Cox KA, McRae DD (2003). Investigation of a novel

condensation aerosol generator: solute and solvent effects. Aerosol Sci Technol. 37:

672–681X.

Hartwig S, Heike GB (2004). A novel spray-drying technique to produce low density

particles for pulmonary delivery. Int J Pharm. 278 (1): 187-195.

Haughney J, Price D, Barnes NC, Virchow JC, Roche N, Chrystyn H (2010).

Choosing inhaler devices for people with asthma: current knowledge and outstanding

research needs. Respir Med. 104: 1237–1245.

Herring VL, Johnson JA (2000). Simple method for determination of terbutaline

plasma concentration by high-performance liquid chromatography. J Chromatogr B

Biomed Sci Appl. 741 (2): 307-12.

Hersch EM, Petersen EA, Proffitt RT, Bracken KR, Chiang SM (1999). Antibiotic

formulation and use for bacterial infections. US5958449.



Hersey JA (1975). Ordered mixing: a new concept in powder mixing practice.

Powder Technol. 11: 41–44.

Heyder J, Gebhart J, Rudolf G, Schiller CF, Stahlhofen W (1986). Deposition of

particles in the human respiratory tract in the size range 0.005–15 [mu]m. J Aerosol

Sci. 17: 811–25.

Hezave AZ, Esmaeilzadeh F (2010). Micronization of drug particles via RESS proces.

J Supercrit Fluids. 52 (1): 84-98.

Hickey AJ, Concessio NM (1997). Descriptors of irregular particle morphology and

powder properties. Adv Drug Deliv Rev. 26: 29–39.

Hickey AJ, Crowder, T.M (2007). Next generation dry powder inhalation delivery

systems. Lung Biol Health Dis. 221: 445–460.

Hickey AJ, Gonda I, Irwin WJ, Fildes FJ (1990). Effect of hydrophobic coating on the

behavior of a hygroscopic aerosol powder in an environment of controlled

temperature and relative humidity. J Pharm Sci. 79 (11): 1009–1014.

Hickey AJ, Martonen TB (1993). Behavior of hygroscopic pharmaceutical aerosols

and the influence of hydrophobic additives. Pharm Res. 10 (1): 1–7.

Hinds WC (1999). Uniform Particle Motion. Aerosol Technology: Properties,

Behavior and Measurement of Airborne Particles (2nd Edn.), pp. 53–5.

Hinrichs WLJ, Mancenido FA, Sanders NN, Braeckmans K, De Smedt SC,

Demeester J (2006). The choice of a suitable oligosaccharide to prevent aggregation

of PEGylated nanoparticles during freeze-thawing and freeze drying. Int J Pharm.

311: 237–44.

Hirst PH, Pitcairn GR, Weers JG, Tarara TE, Clark AR, Dellamary LA, Hall G, Shorr

J, Newman SP (2002). In vivo deposition of hollow porous particles from a

pressurized metered dose inhaler. Pharm Res. 19: 258-264.

Hochhaus G, Möllmann H (1992). Pharmacokinetic/pharmacodynamics

characteristics of the β2-agonists terbutaline, salbutamol and Fenoterol. Int J Clin

Pharmacol. 30 (9): 342-362.



Hodson PD, Smith DK, Velasquez DJ, Wass ACL, Calhoun CD (1998). Dry powder

inhalation device with elongate carrier for power. US5740793.

Holt PG, Strickland DH, Wikstrom ME, Jahnsen FL (2008). Regulation of

immunological homeostasis in the respiratory tract. Nat Rev Immunol. 8: 142–52.

Hong JN, Hindle M, Byron PR (2002). Control of particle size by coagulation of

novel condensation aerosols in reservoir chambers. J Aerosol Med. 15: 359–368.

Hsu CH, Robinson CP, Basmadjian GP (1994). Tissue distribution of 3H-terbutaline

in rabbits. Life Sciences. 54 (20): 1465-1469.

http://www.ginasthma.org/pdf/GINA_Report_2010.pdf

Hu T, Chiou H, Chan HK, Chen JF, Yun J (2008). Preparation of inhalable

salbutamol sulphate using reactive high gravity controlled precipitation. J Pharm Sci.

97: 944–949.

Hussein K, Türk M, Wahl MA (2008). Drug loading into β-cyclodextrin granules

using a supercritical fluid process for improved drug dissolution. Eur J Pharm Sci. 3

(3): 306-312.

J.M.L. Penninger, ACS Symposium Series 406, American Chemical Society:

Washington DC, pp. 334-354.

Jaafar-Maalej C, Andrieu V, Elaissari A, Fessi H (2009). Assessment methods of

inhaled aerosols: technical aspects and applications. Expert Opin Drug Deliv. 6:

941–959.

Jacob JS, Jong YS, Abramson DT, Mathiowitz E, Santos CA (2005). Nanoparticulate

therapeutic biologically active agents. US2005181059.

Jacobs C, Muller RH (2002). Production and characterization of a budesonide

nanosuspension for pulmonary administration. Pharm Res. 19: 189-94.

James J, Crean B, Davies M, Toon R, Jinks P, Roberts CJ (2008). The surface

characterisation and comparison of two potential submicron, sugar bulking excipients



for use in low-dose, suspension formulations in metered dose inhalers. Int J Pharm.

361: 209–221.

Jenne JW, Tashkin DP (1993). Beta-adrenergic agonists. In Bronchial Asthma,

Mechanisms and Therapeutics (3rd Edn) edited by E.B. Weiss & M. Stein, Little,

Brown and Company, pp. 700–748.

Joshi MR, Misra AN (1999). Liposomes of terbutaline sulfate: in vitro and in vivo

studies. Indian J Exp Biol. 37 (9): 881-887.

Keck CM, Müller RH (2006). Drug nanocrystals of poorly soluble drugs produced by

high pressure homogenization. Eur J Pharm Biopharm. 62: 3–16.

Kesisoglou F, Panmai S, Wu Y (2007). Nanosizing — oral formulation development

and biopharmaceutical evaluation. Adv Drug Deliv Rev. 59: 631–644.

Kim KH, Kim HJ, Kim JH, Shin SD (2001). Determination of terbutaline enantiomers

in human urine by coupled achiral-chiral high-performance liquid chromatography

with fluorescence detection. J Chromatogr B Biomed Sci Appl. 10, 751 (1): 69-77.

Kim YH, Sioutas C, Fine P, Katherine S. Shing KS (2008). Effect of albumin on

physical characteristics of drug particles produced by supercritical fluid technology.

Powder Technol. 182 (3): 354-363.

Korn SH, Wouters EF, Wesseling G, Arends JW, Thunnissen FB (1998). Interaction

between glucocorticoids and beta2-agonists: alpha and beta glucocorticoid-receptor

mRNA expression in human bronchial epithelial cells. Biochem Pharmacol. 15, 56

(12): 1561-1569.

Kumar TMP, Shivakumar HG (2006). Novelcore in cup buccoadhesive systems and

films of terbutaline sulphate. Asian J Pharm Sci. 1 (3-4): 175-187.

Lai SK, O'Hanlon DE, Harrold S, Man ST, Wang YY, Cone R (2007). Rapid

transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl

Acad Sci. 104: 1482–7.

Lai SK, Wang YY, Hanes J (2009). Mucus-penetrating nanoparticles for drug and

gene delivery to mucosal tissues. Adv Drug Deliv Rev. 61: 158–71.



Lee J, Lee SJ, Choi JY, Yoo JY, Ahn CH (2005). Amphiphilic amino acid

copolymers as stabilizers for the preparation of nanocrystal dispersion. Eur J Pharm.

Sci. 24 (5): 441-449.

Lemanske RF, Busse WW (2010). Asthma: clinical expression and molecular

mechanisms. J Allergy Clin Immunol. 125 (2): S95–102.

Lengsfeld CS, Delplanque JP, Barocas VH, Randolph TW (2000). Mechanism

governing microparticle morphology during precipitation by a compressed

antisolvent: atomization vs nucleation and growth. J Phys Chem B. 104: 2725-2735.

Li S, Wang J, Zhao S. Determination of terbutaline sulfate by capillary

electrophoresis with chemiluminescence detection (2009). J Chromatogr B Analyt

Technol Biomed Life Sci. 15, 877 (3): 155-58.

Lippmann M, Schlesinger R (1984). Interspecies comparisons of particle deposition

and mucociliary clearance in tracheobronchial airways. J Toxico1 Environ Health.

13(2-3): 441-69.

Lipworth B (1996). Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol. 42:

697-705.

Lou H, Zhang X, Gao L, Feng F, Wang J, Wei X, Yu Z, Zhang D, Zhang Q (2009). In

vitro and in vivo antitumor activity of oridonin nanosuspension. Int J Pharm. 379(1):

181-186.

Lukas P, Anderson K, Staniforth JN (1998). Fine particles multiplets as perforemence

modifiers. Pharm Res. 15: 562-569.

Luo W, Zhu L, Deng J, Liu A, Guo B, Tan W, Dai R (2010). Simultaneous analysis of

bambuterol and its active metabolite Terbutaline enantiomers in rat plasma by chiral

liquid chromatography–tandem mass spectrometry. J Pharm Biomed Anal. 52, 227–

231.

Madl AK, Pinkerton KE (2009). Health effects of inhaled engineered and incidental

nanoparticles. Crit Rev Toxicol. 39: 629–658.



Martín A, Cocero MJ (2008). Micronization processes with supercritical fluids:

fundamentals and mechanisms. Adv Drug Deliv Rev. 60: 339–350.

Martindale (1996). The Extra Pharmacopeia, 28th ed, The Royal Pharmaceutical

Society, London, pp. 1592-1593.

Martinez FD (2007). Genes, environments, development and asthma: a reappraisal.

Eur Respir J. 29 (1): 179–84.

Martonen TB, Katz I, Fults K, Hickey AJ (1992). Use of analytically defined

estimates of aerosol respirable fraction to predict lung deposition patterns. Pharm

Res. 9 (12): 1634–1639.

Maschke A, Calí N, Appel B, Kiermaier J, Blunk T Göpferich A (2006)

Micronization of Insulin by High Pressure Homogenization. Pharm Res. 23(9): 2220-

2229.

Mason, Robert J; Broaddus, V Courtney; Murray, John F; Nadel, Jay A (2005).

Asthma. Murray and Nadel's Textbook of Respiratory Medicine (4th Eds.), Elsevier.

Matsukawa Y, Lee VH, Crandall ED, Kim KJ (1997). Size-dependent dextran

transport across rat alveolar epithelial cell monolayers. J Pharm Sci. 86: 305–9.

Matteucci ME, Hotze MA, Johnston KP, Williams III RO (2006). Drug nanoparticles

by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir.

22: 8951–8959.

Mauludin R, Müller RH, Keck CM (2009). Development of an oral rutin nanocrystal

formulation. Int J Pharm. 370 (1-2): 202-209.

McWilliam AS, Holt PG, Gehr P (2000). Dendritic cells as sentinels of immune

surveillance in the airways. In Particle–Lung Interactions edited by P. Gehr & J.

Heyder, Marcel Dekker Inc., New York, pp. 473–489.

Mercer RR, Russell ML, Roggli VL, Crapo JD (1994). Cell number and distribution

in human and rat airways. Am J Respir Cell Mol Biol. 10: 613–24.



Merkus HG (2008). Particle Size Measurements: Fundamentals, Practice, Quality,

Springer, USA.

Meziani MJ, Pathak P, Beacham F, Allard LF, Sun YP (2005). Nanoparticle

formation in rapid expansion of water-in-supercritical carbon dioxide microemulsion

into liquid solution. J Supercrit Fluids. 34(1): 91-97.

Mie A, Ray A, Axelsson BO, Jörntén-Karlsson M, Reimann CT (2008). Terbutaline

enantiomer separation and quantification by complexation and field asymmetric ion

mobility spectrometry-tandem mass spectrometry. Anal Chem. 80 (11): 4133-40.

Mitchell JP, Nagel MW (2003). Cascade impactors for the size characterization of

aerosols from medical inhalers: their use and limitations. J Aerosol Med.16: 341-377.

Moller W, Felten K, Sommerer K, Scheuch G, Meyer G, Meyer P (2008). Deposition,

retention, and translocation of ultrafine particles from the central airways and lung

periphery. Am J Respir Crit Care Med. 177: 426–32.

Moore WC, Pascual RM (2010). Update in asthma 2009. Am J Res Crit Care Med.

181 (11): 1181–7.

Moribe K, Fukino M, Tozuka Y, Higashi K, Yamamoto K (2009). Prednisolone

multicomponent nanoparticle preparation by aerosol solvent extraction system. Int J

Pharm. 380(1-2): 201-205.

Moulton B, Zaworotko MJ (2001). From molecules to crystal engineering:

supramolecular isomerism and polymorphism in network solids. Chem Rev. 101 (6):

1629–1658.

Muller RH, Jacobs C, Kayser O (2001). Nanosuspensions as particulate drug

formulations in therapy rationale for development and what we can expect for the

future. Adv Drug Deliv Rev. 47: 3–19.

Newman S, Hollingworth A, Clark A (1994). Effect of different modes of inhalation

on drug delivery from a dry powder inhaler. Int J Pharm. 102 (1):127–132.

Newman SP (2004). Dry powder inhalers for optimal drug delivery. Expert Opin

Biol Ther. 4: 23–33.



Newman SP, Busse WW (2002). Evolution of dry powder inhaler design, formulation

and performance. Respir Med. 96: 293–304.

Newman SP, Busse WW (2002). Evolution of dry powder inhaler design,

formulation, and performance. Respir Med. 96: 293–304.

Newman SP, Clarke SW (1983). Therapeutic aerosols I—physical and practical

considerations. Thorax. 38: 881–886.

Newman SP, Clarke SW (1993). Bronchodilator delivery from Gentlehaler, a new

low-velocity pressurized aerosol inhaler. Chest. 103 (5):1442–1446.

Newman SP, Pitcairn GR, Hirst PH, Rankin L (2003). Radionuclide imaging

technologies and their use in evaluating asthma drug deposition in the lungs. Adv

Drug Deliv Rev. 55: 851–867.

Newman SP, Wilding IR (1998). Gamma scintigraphy: an in vivo technique for

assessing the equivalence of inhaled products. Int J Pharm. 170: 1–9.

Newman SP, Wilding IR (1999). Imaging techniques for assessing drug delivery in

man. Pharm Sci Technol Today 2: 181–189.

NIOSH (2005). Strategic Plan for NIOSH Nanotechnology Research and Guidance –

Filling the Knowledge Gap. Nanotechnology Research Program, Centers for Disease

Control and Prevention, National Institute for Occupational Safety and Health, pp.

103.

Niwa T, Shimabara H, Kondo M, Danjo K (2009). Design of porous microparticles

with single-micron size by novel spray freeze-drying technique using four-fluid

nozzle. Int J Pharm. 382 (1-2): 88-97.

Nov´akov L, Matysov L and Solich P (2006). Advantages of application of UPLC in

pharmaceutical analysis. Talanta. 68: 908–918.

Nyberg L (1984). Pharmacokinetic parameters of terbutaline in healthy man. An

overview. Eur J Respir Dis. 65 (134): 149–160.



Oberdörster G (2007). Biokinetics and effects of nanoparticles. In Nanotechnology—

Toxicological Issues and Environmental Safety edited by P.P. Simeonova, N.

Opopol, M.I. Luster, Springer, Netherlands, pp. 15–51.

Okamoto H, Danjo K (2008). Application of supercritical fluid to preparation of

powders of high-molecular weight drugs for inhalation. Adv Drug Deliv Rev. 60:

433–446.

Okuyama K, Wuled Lenggoro I (2003). Preparation of nanoparticles via spray route.

Chem Eng Sci. 58: 537–547.

Olmsted SS, Padgett JL, Yudin AI, Whaley KJ, Moench TR, Cone RA (2001).

Diffusion of macromolecules and virus-like particles in human cervical mucus.

Biophys J. 81: 1930–7.

Orlovius AK, Guddat S, Parr MK, Kohler M, Gütschow M, Thevis M, Schnzer W

(2009). Terbutaline sulfoconjugate: characterization and urinary excretion monitored

by LC/ESI-MS/MS. Drug Test Anal. 1: 554–568.

Ostrander KD, Bosch HW, Bondanza DM (1999). An in-vitro assessment of a

nanocrystal beclomethasone dipropionate colloidal dispersion via ultrasonic

nebulization. Eur J Pharm Biopharm. 48: 207–215.

Overhoff KA, Engstrom JD, Chen B, Scherzer BD, Milner TE, Johnston KP,

Williams III RO (2007). Novel ultra-rapid freezing particle engineering process for

enhancement of dissolution rates of poorly water-soluble drugs. Eur J Pharm

Biopharm. 65: 57–67.

Pacifici GM, Eligi M, Giuliani L (1993). (+) and (-) terbutaline are sulfated at a higher

rate in human intestine than in liver. Eur J Clin Pharmacol. 45: 483-487.

Palakodaty S, York P (1999). Phase behavioral effects on particle formation processes

using supercritical fluids. Pharm Res. 16: 976-985.

Palakurthi S, Govardhanachary M, Vyas SP, Diwan PV (2000). Biodistribution of

liposomes of terbutaline sulfate in guinea pigs. Drug Dev Ind Pharm. 26 (10): 1099-

1105.



Panagiotou T, Fisher RJ (2008). Form nanoparticles via controlled crystallization.

Chem Eng Prog. 104: 33–39.

Parkes WR (1994). Morphology of the respiratory tract. In Occupational Lung

Disorders, (3rd Edn.), pp. 1–17.

Pasquali I, Bettini R, Giordano F (2008). Supercritical fluid technologies: an

innovative approach for manipulating the solid-state of pharmaceuticals. Adv Drug

Deliv Rev. 60: 399–410.

Pathak P, Meziani MJ, Desai T, Sun YP (2006). Formation and stabilization of

ibuprofen nanoparticles in supercritical fluid processing. J Supercrit Fluids. 37: 279-

286.

Patravale VB, Date AA, Kulkarni RM (2004). Nanosuspensions: a promising drug

delivery strategy. J Pharm Pharmacol. 56: 827–840.

Patton JS, Bukar J, Nagarajan S (1999). Inhaled insulin. Adv Drug del Rev. 35: 235-

247.

Peart J, Clarke MJ (2001). New developments in dry powder inhaler technology. Am

Pharm Rev. 4: 37–45.

Perez-Gil J (2008). Structure of pulmonary surfactant membranes and films: the role

of proteins and lipid–protein interactions. Biochim Biophys Acta. 1778: 1676–95.

Physicians Desk Reference (2002). 56th Edn., pp. 2313-2315.

Pilcer G, Amighi K (2010). Formulation strategy and use of excipients in pulmonary

drug delivery. Int J Pharm. 392: 1–19.

Pilcer G, Vanderbist F, Amighi K (2008). Correlations between cascade impactor

analysis and laser diffraction techniques for the determination of the particle size of

aerosolised powder formulations. Int J Pharm. 358: 75–81.

Pitcairn GR, Lankinen T, Seppala OP, Newman SP (2000). Pulmonary drug delivery

from the Taifun dry powder inhaler is relatively independent of the patient’s

inspiratory effort. J Aerosol Med. 13: 97–104.



Plumb R, Castro-Perez J, Gragner J, Beattie I, Joncour K, Wright A (2004). Ultra-

erformance liquid chromatography coupled to quadrupole-orthogonal time-of-flight

mass spectrometry. Rapid Com Mass Spec. 19: 2331–2337.

Qamar W, Sultana S (2008). Farnesol ameliorates massive inflammation, oxidative

stress and lung injury induced by intratracheal instillation of cigarette smoke extract

in rats: An initial step in lung chemoprevention. Chem. Biol. Interact. 176: 79-87.

Quintanar-Guerrero D, Fessi H, Alemann E, Doelker E (1996). Influence of

stabilizing agent and preparative variables on the formation poly(D,L-Lactic acid)

nanoparticles by an emulsion-diffusion process. Int. J Pharm. 143: 133-141.

Rabinow BE (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov. 3:

785–796.

Radhakrishnan R (1991). Novel liposome composition for the treatment of interstitial

lung diseases. US5049389.

Radhakrishnan R, Mihalko PJ, Abra RM (1993). Corticosteroid inhalation treatment

method. US5192528.

Rasenack N., Mueller B.W (2004). Micron-size drug particles: common and novel

micronization techniques. Pharm Dev Technol. 9: 1–13.

Raula J, Eerikainen H, Kauppinen EI (2004). Influence of the solvent composition on

the aerosol synthesis of pharmaceutical polymer nanoparticles. Int J Pharm. 13: 13-

21.

Reddy LH, Sharma RK, Chuttani K, Mishra AK, Murthy RR (2004). Etoposide

incorporated tripalmitin nanoparticles with different surface charge: formulation,

characterization, radiolabeling, and biodistribution studies. AAPS J. 6: e23.

Reverchon E, Adami R. (2006), Nanomaterials and supercritical fluids. J Supercrit

Fluids. 37 (1–22): 112–114.

Reverchon E, Donsi G (1993). Salicylic acid solubilization in supercritical CO2 and

its micronization by RESS. J Supercrit. Fluids. 6: 241-248.



Reverchon E, Porta GD (2003). Terbutaline microparticles suitable for aerosol

delivery produced by supercritical assisted atomization. Int Jour Pharm. 258 (1-2):

1-9.

Reverchon E, Porta GD, Taddeo T (1995). Solubility and micronization of

griseofulvin in supercritical CHF3. Ind Eng Chem Res. 34: 4087-4091.

Rodriguez-Hornedo N, Sinclair BD (2002). Crystallization: significance in product

development, processing and performance. In Encyclopedia of pharmaceutical

technology edited by J. Swarbrick & J.C. Boylan, Dekker, New York.

Rogers TL, Nelsen AC, Hu J, Brown JN, Sarkari M, Young TJ, Johnston KP,

Williams III RO (2002). A novel particle engineering technology to enhance

dissolution of poorly water soluble drugs: spray-freezing into liquid. Eur J Pharm

Biopharm. 54: 271–280.

Rosenborg J (2002). Clinical-pharmacokinetic aspects of prolonged effect duration as

illustrated by β2-agonists. Eur J Clin Pharmacol. 58 (4): 1-21.

Ryrfeldt A, Nilsson E (1978). Uptake and biotransformation of ibuterol and

terbutaline in isolated perfused rat and guinea pig lungs. Biochem Pharmacol. 27:

301-305.

Ryrfelt A, Ramsay CH. Distribution of terbutaline, Eur. J. Respir. Dis., 65 (Suppl

134), 63-72, 1984.

Sahin S, Selek H, Ponchel G, Ercan MT, Sargon M, Hincal AA, Kas HS (2002).

Preparation, characterization and in vivo distribution of terbutaline sulfate loaded

albumin microspheres. Jour Control Rel. 82 (2-3): 345-358.

Sakagami M (2006). In vivo, in vitro and ex vivo models to assess pulmonary

absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug

Deliv Rev. 58: 1030–1060.

Sakagami M (2006). In vivo, in vitro and ex vivo models to assess pulmonary

absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug

Deliv Rev. 58: 1030–1060.



Schmid O, Moller W, Semmler-Behnke M, Ferron GA, Karg E, Lipka J, Schulz H,

Kreyling WG, Stoeger T (2009). Dosimetry and toxicology of inhaled ultrafine

particles. Biomarkers. 14 (1): 67–73.

Shahgaldian P, Gualbert J, Aýssa K, Coleman AW (2003). A study of the freeze

drying conditions of calixarene based solid lipid nanoparticles. Eur J Pharm

Biopharm. 55: 181–84.

Sharma R, Saxena D, Dwivedi AK, Misra A (2001). Inhalable microparticles

containing drug combinations to target alveolar macrophages for treatment of

pulmonary tuberculosis. Pharm Res. 18: 1405–1410.

Shekunov BY, York P (2002). Crystallization processes in pharmaceutical technology

and drug delivery design. J Crystal Growth. 211: 122-136.

Shikov AN, Pozharitskaya ON, Miroshnyk I, Mirza S, Urakova IN, Hirsjärvi S,

Makarov VG, Heinämäki J, Yliruusi J, Hiltunen R (2009). Nanodispersions of

taxifolin: Impact of solid-state properties on dissolution behavior. Int J Pharm. 377

(1-2): 148-152.

Simis K, Lei M, Lu AT, Sharma KCV, Hale RL, Timmons R, Cassella J (2008).

Nicotine aerosol generation from thermally reversible zinc halide complexes using the

staccato® system. Drug Dev Ind Pharm. 34: 936–942.

Singh DJ, Parmar JJ, Hegde DD, Lohade AA, Soni P, Samad A, Mala MD (2010).

Development and Evaluation of Dry Powder Inhalation System of Terbutaline

Sulphate for Better Management of Asthma. Int J Adv Pharm Sci. 2: 133-141.

Sinswat P, Overhoff KA, McConville JT, Johnston KP, Williams III RO (2008).

ebulization of nanoparticulate amorphous or crystalline tacrolimus—singledose

pharmacokinetics study in mice. Eur J Pharm Biopharm. 69: 1057–1066.

Smyth HD, Hickey AJ (2005). Carriers in drug powder delivery: implications for

inhalation system design. Am J Drug Deliv. 3 (2): 117–132.

Snell NJC, Ganderton D (1999). Assessing lung deposition of inhaled medications:

consensus statement from a workshop of the British association for Lung research,



held at the Institute of Biology, London, U.K. On 17 April 1998, Respir Med. 93

123–133.

Spisso BF, Lopes CC, Marques MA, Neto FR (2000). Determination of beta2-

agonists in bovine urine: comparison of two extraction/clean-up procedures for high-

resolution gas chromatography-mass spectrometry analysis. Journ Anal Toxicol. 24:

146–52.

Stahl, K, Claesson M, Lilliehorn P, Linden H, Backstrom K (2002). The effects of

process variables on the degradation and physical properties of spray dried insulin

intended for inhalation. Int J Pharm. 233: 227-237.

Stainmesse S, Orecchioni AM, Nakache E, (1992). Modelling of an original process

to obtain biocompatible polymeric nanospheres. Proc Sixth Congr Int Technol

Pharm. 1: 89–97.

Stamenkovic I (2003). Extracellular matrix remodelling: the role of matrix metallo-

proteinases. J Pathol. 200: 448–64.

Staniforth, J.N (1995). Development of dry powder inhalers. WO9511666.

Stevenson DD, Szczeklik A (2006). Clinical and pathologic perspectives on aspirin

sensitivity and asthma. J Allergy Clin Immunol. 118 (4): 773–86.

Stoica C, Verwer P, Meekes H (2004). Understanding the effect of a solvent on the

crystal habit. Crys Growth Design. 4 (4):765–768.

Su CS, Tang M, Chen YP (2009). Micronization of nabumetone using the rapid

expansion of supercritical solution (RESS) process. The J Supercrit Fluids. 50 (1):

69-76.

Subramaniam B, Rajewski RA, Snavely K (1997). Pharmaceutical processing with

supercritical carbon dioxide. J Pharm Sci. 86: 885-890.

Taburet AM, Schmit B (1994). Pharmacokinetic optimization of asthma treatment.

Clin Pharmacokinet. 26: 396-418.



Takenaka S, Karg E, Kreyling WG, Lentner B, Moller W, Behnke-Semmler M

(2006). Distribution pattern of inhaled ultrafine gold particles in the rat lung. Inhal

Toxicol. 18: 733–40.

Tam JM, Engstrom JD, Ferrer D, William III RO, Johnston KP (2010). Templated

open flocs of anisotropic particles for pulmonary delivery with pressurized metered

dose inhalers. J Pharm Sci. 99: 3150–3165.

Tam JM, McConville JT, Williams III RO, Johnston KP (2008). Amorphous

cyclosporine nanodispersions for enhanced pulmonary deposition and dissolution. J

Pharm Sci. 97: 4915–4933.

Taylor J, Kotch A, Rice K, Ghafouri M, Kurland CL, Fagan NA, Witek TJ (2002).

Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in

patients with COPD. Chest. 120: 1253-1261.

Tetley TD (2002). Macrophages and the pathogenesis of COPD. Chest. 121: 156S–

9S.

Thirstrup S, Nielsen-Kudsk F, Dahl R (1997). In vitro studies on the interactions of

beta2-adrenoceptor agonists, methylxanthines, Ca2+-channel blockers, K+-channel

openers and other airway smooth muscle relaxants in isolated guinea-pig trachea. Eur

J Pharmacol. 20, 326(2-3): 191-200.

Thybo P, Hovgaard L, Lindeløv J, Brask A, Andersen S (2008). Scaling up the spray

drying process from pilot to production scale using an atomized droplet size criterion.

Pharm Res. 25: 1610–1620.

Timsina MP, Martin GP, Marriott C (1994). Drug-delivery to the respiratory-tract

using dry powder inhalers. Int J Pharm. 101 (1): 1–13.

Tozuka Y, Miyazaki Y, Takeuchi H (2010). A combinational supercritical CO2

system for nanoparticle preparation of indomethacin. Int. J Pharm. 386(1-2): 243-8.

Tristan P, Burrows JLL, French EB, Seville PC (2008). Chitosan-based spray-dried

respirable powders for sustained delivery of terbutaline sulfate. Eur Journ Pharm

Biopharm. 68 (2): 224-234.



Trofast Jan (1998). New formulation for inhalation having a poured bulk density of

from 0.28 to 0.38 g/ml, comprising Formoterol. WO9831351.

Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA (2002). Trojan particles:

large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci. 99:

12001–5.

Tung HH, Paul EL, Midler M, McCauley JA (2009). Crystallization of Organic

Compounds, Wiley & Sons Inc., USA.

Ultra Performance LCTM by design (2004). Waters Corporation, USA, 720000880 EN

LL & LW-UL.

USFDA (2011). Guidance for Industry Bioanalytical Method Validation.

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/G

uidances/UCM070107.pdf

Usmani OS (2009). In Delivery of drugs to the airways edited by O.S. Usmani,

Lung Biol Health Dis., pp. 143–161.

USP (2005). <601> aerosols, nasal sprays, metered-dose inhalers, and dry powder

inhalers, U.S. Pharmacopeia, pp. 32.

Van der Schans CP (2007). Bronchial mucus transport. Respir Care. 52: 1150–6.

Van der Velden V, Hulsmann AR (1999). Peptidases: structure, function and

modulation of peptide-mediated effects in the human lung. Clin Exp Allergy. 29:

445–56.

Varshosaz J, Hassanzadeh F, Mahmoudzadeh M, Sadeghi A (2009). Preparation of

cefuroxime axetil nanoparticles by rapid expansion of supercritical fluid technology.

Powder Tech. 189 (1): 97-102.

Varum FJ, McConnell EL, Sousa JJ, Veiga F, Basit AW (2008). Mucoadhesion and

the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst. 25: 207–58.

Vehring R (2008). Pharmaceutical particle engineering via spray drying, Pharm Res.

25: 999–1022.



Verma S, Gokhale R, Burgess DJ (2009a). A comparative study of top-down and

bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm.

380 (1-2): 216-222.

Verma S, Lan Y, Gokhale R, Burgess DJ (2009). Quality by design approach to

understand the process of nanosuspension preparation. Int J Pharm. 377 (1-2): 185-

198.

Videira MA, Botelho MF, Santos AC, Gouveia LF, de Lima JJP, Almeida AJ (2002).

Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J

Drug Target. 10: 607–613.

Virchow JC, Kroegel C, Matthys H (1994). Antiasthma drug delivery: what is on the

horizon. Clin. Pharmacokinet. 27: 85-93.

Vogt M, Kunath K, Dressman JB (2008). Dissolution enhancement of fenofibrate by

micronization, cogrinding and spray-drying: Comparison with commercial

preparations. Eur J Pharm Biopharm. 68(2): 283-288.

Wanawongthai C, Pongpeerapat A, Higashi K, Tozuka Y, K. Moribe K, Yamamoto K

(2009). Nanoparticle formation from probucol/PVP/sodium alkyl sulfate co-ground

mixture. Int. J Pharm. 376(1-2): 169-175.

Wang Z, Zhang Z, Fu Z, Chen D, Zhang X (2003). Flow-injection

chemiluminescence detection for studying protein binding of terbutaline sulfate with

on-line microdialysis sampling. J Pharm Biomed Anal. 24, 33 (4): 765-73.

Wang Z, Zhang Z, Fu Z, Zhang X (2004). Sensitive flow-injection

chemiluminescence determination of terbutaline sulfate based on enhancement of the

luminol-permanganate reaction. Anal Bioanal Chem. 378 (3): 834-40.

Weers JG, Tarara TE, Clark AR (2007). Design of fine particles for pulmonary drug

delivery. Expert Opin Drug Deliv. 4: 297–313.

Wiedmann TS, DeCastro L, Wood RW (1997). Nebulization of NanoCrystals™:

production of a respirable solid-in-liquid-in-air colloidal dispersion. Pharm Res. 14:

112–116.



Y.J. Son, J.T. McConville (2009). Development of a standardized dissolution test

method for inhaled pharmaceutical formulations. Int J Pharm. 382: 15–22.

Yacobi NR, Demaio L, Xie J, Hamm-Alvarez SF, Borok Z, Kim KJ (2008).

Polystyrene nanoparticle trafficking across alveolar epithelium. Nanomedicine. 4:

139–45.

Yang HJ, Chu GW, Zhang JW, Shen ZG, Chen JF (2005). Micromixing efficiency in

a rotating packed bed: experiments and simulation. Ind Eng Chem Res. 44: 7730–

7737.

Yang W, Johnston KP, Williams III RO (2010). Comparison of bioavailability of

amorphous versus crystalline itraconazole nanoparticles via pulmonary administration

in rats. Eur J Pharm Biopharm. 75: 33–41.

Yang W, Peters JI, Williams RO (2008a). Inhaled nanoparticles —a current review,

Int J Pharm. 356: 239–247.

Yang W, Tam J, Miller DA, Zhou J, McConville JT, Johnston KP, Williams III RO

(2008). High bioavailability from nebulized itraconazole nanoparticle dispersions

with biocompatible stabilizers. Int J Pharm. 361: 177–188.

York P (1999). Strategies for particle design using supercritical fluid technologies.

Pharm Sci Tech Today. 2: 430-440.

Yudin AI, Hanson FW, Katz DF (1989). Human cervical mucus and its interaction

with sperm: a fine-structural view. Biol Reprod. 40: 661–71.

Zeng XM, Martin GP, Marriott C, Pritchard J (2000). The influence of carrier

morphology on drug delivery by dry powder inhalers. Int J Pharm. 200: 93–106.

Zhang HX, Wang JX, Zhang ZB, Le Y, Shen ZG, Chen JF (2009). Micronization of

atorvastatin calcium by antisolvent precipitation process. Int. J Pharm. 374 (1-2):

106-113.

Zhang JY, Shen ZG, Zhong J, Hu TT, Chen JF, Ma ZQ, Yun J (2006). Preparation of

amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method

without surfactants. Int. J Pharm. 323 (1-2): 153-160.



Zhang ZB, Shen ZG, Wang JX, Zhang HX, Zhao H, Chen JF, Yun J (2009a).

Micronization of silybin by the emulsion solvent diffusion method. Int. J Pharm. 376

(1-2): 116-122.

Zhao H., Shao L., Chen J.F., High-gravity process intensification technology and

application, Chem. Eng. J. 156 (2010) 588–593.

Chapter 7 References -...

Documents

Transcript of Chapter 7 References -...